Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies

A history of statins and experience from a large international multi-center study

Lucile Musset, Yves Allenbach, Olivier Benveniste, Olivier Boyer, Xavier Bossuyt, Chelsea Bentow, Joe Phillips, Andrew Mammen, Philip Van Damme, René Westhovens, Anna Ghirardello, Andrea Doria, May Y. Choi, Marvin J. Fritzler, Heinrike Schmeling, Yoshinao Muro, Ignacio García-De La Torre, Miguel A. Ortiz-Villalvazo, Nicola Bizzaro, Maria Infantino & 12 others Tiziana Imbastaro, Qinglin Peng, Guochun Wang, Jiří Vencovský, Martin Klein, Olga Krystufkova, Franco Franceschini, Micaela Fredi, Sophie Hue, Thibaut Belmondo, K. Dankó, Michael Mahler

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

In an effort to find naturally occurring substances that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), statins were first discovered by Endo in 1972. With the widespread prescription and use of statins to decrease morbidity from myocardial infarction and stroke, it was noted that approximately 5% of all statin users experienced muscle pain and weakness during treatment. In a smaller proportion of patients, the myopathy progressed to severe morbidity marked by proximal weakness and severe muscle wasting. Remarkably, Mammen and colleagues were the first to discover that the molecular target of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), is an autoantibody target in patients that develop an immune-mediated necrotizing myopathy (IMNM). These observations have been confirmed in a number of studies but, until today, a multi-center, international study of IMNM, related idiopathic inflammatory myopathies (IIM), other auto-inflammatory conditions and controls has not been published. Accordingly, an international, multi-center study investigated the utility of anti-HMGCR antibodies in the diagnosis of statin-associated IMNM in comparison to different forms of IIM and controls. This study included samples from patients with different forms of IIM (n = 1250) and patients with other diseases (n = 656) that were collected from twelve sites and tested for anti-HMGCR antibodies by ELISA. This study confirmed that anti-HMGCR autoantibodies, when found in conjunction with statin use, characterize a subset of IIM who are older and have necrosis on muscle biopsy. Taken together, the data to date indicates that testing for anti-HMGCR antibodies is important in the differential diagnosis of IIM and might be considered for future classification criteria.

Original languageEnglish
JournalAutoimmunity Reviews
DOIs
Publication statusAccepted/In press - Jul 7 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscular Diseases
Coenzyme A
Myositis
Oxidoreductases
Biomarkers
Antibodies
Muscle Weakness
Autoantibodies
Morbidity
Myalgia
Prescriptions
Differential Diagnosis
Necrosis
Enzyme-Linked Immunosorbent Assay
Stroke
Myocardial Infarction
Cholesterol
Biopsy
Muscles

Keywords

  • Autoantibodies
  • Autoimmune myositis
  • HMGCR
  • Immune-mediated necrotizing myopathy
  • Statins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Cite this

Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies : A history of statins and experience from a large international multi-center study. / Musset, Lucile; Allenbach, Yves; Benveniste, Olivier; Boyer, Olivier; Bossuyt, Xavier; Bentow, Chelsea; Phillips, Joe; Mammen, Andrew; Van Damme, Philip; Westhovens, René; Ghirardello, Anna; Doria, Andrea; Choi, May Y.; Fritzler, Marvin J.; Schmeling, Heinrike; Muro, Yoshinao; García-De La Torre, Ignacio; Ortiz-Villalvazo, Miguel A.; Bizzaro, Nicola; Infantino, Maria; Imbastaro, Tiziana; Peng, Qinglin; Wang, Guochun; Vencovský, Jiří; Klein, Martin; Krystufkova, Olga; Franceschini, Franco; Fredi, Micaela; Hue, Sophie; Belmondo, Thibaut; Dankó, K.; Mahler, Michael.

In: Autoimmunity Reviews, 07.07.2016.

Research output: Contribution to journalArticle

Musset, L, Allenbach, Y, Benveniste, O, Boyer, O, Bossuyt, X, Bentow, C, Phillips, J, Mammen, A, Van Damme, P, Westhovens, R, Ghirardello, A, Doria, A, Choi, MY, Fritzler, MJ, Schmeling, H, Muro, Y, García-De La Torre, I, Ortiz-Villalvazo, MA, Bizzaro, N, Infantino, M, Imbastaro, T, Peng, Q, Wang, G, Vencovský, J, Klein, M, Krystufkova, O, Franceschini, F, Fredi, M, Hue, S, Belmondo, T, Dankó, K & Mahler, M 2016, 'Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study', Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2016.07.023
Musset, Lucile ; Allenbach, Yves ; Benveniste, Olivier ; Boyer, Olivier ; Bossuyt, Xavier ; Bentow, Chelsea ; Phillips, Joe ; Mammen, Andrew ; Van Damme, Philip ; Westhovens, René ; Ghirardello, Anna ; Doria, Andrea ; Choi, May Y. ; Fritzler, Marvin J. ; Schmeling, Heinrike ; Muro, Yoshinao ; García-De La Torre, Ignacio ; Ortiz-Villalvazo, Miguel A. ; Bizzaro, Nicola ; Infantino, Maria ; Imbastaro, Tiziana ; Peng, Qinglin ; Wang, Guochun ; Vencovský, Jiří ; Klein, Martin ; Krystufkova, Olga ; Franceschini, Franco ; Fredi, Micaela ; Hue, Sophie ; Belmondo, Thibaut ; Dankó, K. ; Mahler, Michael. / Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies : A history of statins and experience from a large international multi-center study. In: Autoimmunity Reviews. 2016.
@article{703a703340f84ede8085c922b27910db,
title = "Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study",
abstract = "In an effort to find naturally occurring substances that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), statins were first discovered by Endo in 1972. With the widespread prescription and use of statins to decrease morbidity from myocardial infarction and stroke, it was noted that approximately 5{\%} of all statin users experienced muscle pain and weakness during treatment. In a smaller proportion of patients, the myopathy progressed to severe morbidity marked by proximal weakness and severe muscle wasting. Remarkably, Mammen and colleagues were the first to discover that the molecular target of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), is an autoantibody target in patients that develop an immune-mediated necrotizing myopathy (IMNM). These observations have been confirmed in a number of studies but, until today, a multi-center, international study of IMNM, related idiopathic inflammatory myopathies (IIM), other auto-inflammatory conditions and controls has not been published. Accordingly, an international, multi-center study investigated the utility of anti-HMGCR antibodies in the diagnosis of statin-associated IMNM in comparison to different forms of IIM and controls. This study included samples from patients with different forms of IIM (n = 1250) and patients with other diseases (n = 656) that were collected from twelve sites and tested for anti-HMGCR antibodies by ELISA. This study confirmed that anti-HMGCR autoantibodies, when found in conjunction with statin use, characterize a subset of IIM who are older and have necrosis on muscle biopsy. Taken together, the data to date indicates that testing for anti-HMGCR antibodies is important in the differential diagnosis of IIM and might be considered for future classification criteria.",
keywords = "Autoantibodies, Autoimmune myositis, HMGCR, Immune-mediated necrotizing myopathy, Statins",
author = "Lucile Musset and Yves Allenbach and Olivier Benveniste and Olivier Boyer and Xavier Bossuyt and Chelsea Bentow and Joe Phillips and Andrew Mammen and {Van Damme}, Philip and Ren{\'e} Westhovens and Anna Ghirardello and Andrea Doria and Choi, {May Y.} and Fritzler, {Marvin J.} and Heinrike Schmeling and Yoshinao Muro and {Garc{\'i}a-De La Torre}, Ignacio and Ortiz-Villalvazo, {Miguel A.} and Nicola Bizzaro and Maria Infantino and Tiziana Imbastaro and Qinglin Peng and Guochun Wang and Jiř{\'i} Vencovsk{\'y} and Martin Klein and Olga Krystufkova and Franco Franceschini and Micaela Fredi and Sophie Hue and Thibaut Belmondo and K. Dank{\'o} and Michael Mahler",
year = "2016",
month = "7",
day = "7",
doi = "10.1016/j.autrev.2016.07.023",
language = "English",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",

}

TY - JOUR

T1 - Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies

T2 - A history of statins and experience from a large international multi-center study

AU - Musset, Lucile

AU - Allenbach, Yves

AU - Benveniste, Olivier

AU - Boyer, Olivier

AU - Bossuyt, Xavier

AU - Bentow, Chelsea

AU - Phillips, Joe

AU - Mammen, Andrew

AU - Van Damme, Philip

AU - Westhovens, René

AU - Ghirardello, Anna

AU - Doria, Andrea

AU - Choi, May Y.

AU - Fritzler, Marvin J.

AU - Schmeling, Heinrike

AU - Muro, Yoshinao

AU - García-De La Torre, Ignacio

AU - Ortiz-Villalvazo, Miguel A.

AU - Bizzaro, Nicola

AU - Infantino, Maria

AU - Imbastaro, Tiziana

AU - Peng, Qinglin

AU - Wang, Guochun

AU - Vencovský, Jiří

AU - Klein, Martin

AU - Krystufkova, Olga

AU - Franceschini, Franco

AU - Fredi, Micaela

AU - Hue, Sophie

AU - Belmondo, Thibaut

AU - Dankó, K.

AU - Mahler, Michael

PY - 2016/7/7

Y1 - 2016/7/7

N2 - In an effort to find naturally occurring substances that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), statins were first discovered by Endo in 1972. With the widespread prescription and use of statins to decrease morbidity from myocardial infarction and stroke, it was noted that approximately 5% of all statin users experienced muscle pain and weakness during treatment. In a smaller proportion of patients, the myopathy progressed to severe morbidity marked by proximal weakness and severe muscle wasting. Remarkably, Mammen and colleagues were the first to discover that the molecular target of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), is an autoantibody target in patients that develop an immune-mediated necrotizing myopathy (IMNM). These observations have been confirmed in a number of studies but, until today, a multi-center, international study of IMNM, related idiopathic inflammatory myopathies (IIM), other auto-inflammatory conditions and controls has not been published. Accordingly, an international, multi-center study investigated the utility of anti-HMGCR antibodies in the diagnosis of statin-associated IMNM in comparison to different forms of IIM and controls. This study included samples from patients with different forms of IIM (n = 1250) and patients with other diseases (n = 656) that were collected from twelve sites and tested for anti-HMGCR antibodies by ELISA. This study confirmed that anti-HMGCR autoantibodies, when found in conjunction with statin use, characterize a subset of IIM who are older and have necrosis on muscle biopsy. Taken together, the data to date indicates that testing for anti-HMGCR antibodies is important in the differential diagnosis of IIM and might be considered for future classification criteria.

AB - In an effort to find naturally occurring substances that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), statins were first discovered by Endo in 1972. With the widespread prescription and use of statins to decrease morbidity from myocardial infarction and stroke, it was noted that approximately 5% of all statin users experienced muscle pain and weakness during treatment. In a smaller proportion of patients, the myopathy progressed to severe morbidity marked by proximal weakness and severe muscle wasting. Remarkably, Mammen and colleagues were the first to discover that the molecular target of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), is an autoantibody target in patients that develop an immune-mediated necrotizing myopathy (IMNM). These observations have been confirmed in a number of studies but, until today, a multi-center, international study of IMNM, related idiopathic inflammatory myopathies (IIM), other auto-inflammatory conditions and controls has not been published. Accordingly, an international, multi-center study investigated the utility of anti-HMGCR antibodies in the diagnosis of statin-associated IMNM in comparison to different forms of IIM and controls. This study included samples from patients with different forms of IIM (n = 1250) and patients with other diseases (n = 656) that were collected from twelve sites and tested for anti-HMGCR antibodies by ELISA. This study confirmed that anti-HMGCR autoantibodies, when found in conjunction with statin use, characterize a subset of IIM who are older and have necrosis on muscle biopsy. Taken together, the data to date indicates that testing for anti-HMGCR antibodies is important in the differential diagnosis of IIM and might be considered for future classification criteria.

KW - Autoantibodies

KW - Autoimmune myositis

KW - HMGCR

KW - Immune-mediated necrotizing myopathy

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84981717423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981717423&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2016.07.023

DO - 10.1016/j.autrev.2016.07.023

M3 - Article

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

ER -